• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Bandy Barton P.

    6/24/21 5:02:31 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care
    Get the next $OBLN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Bandy Barton P.

    (Last) (First) (Middle)
    1001 CALLE AMANECER

    (Street)
    SAN CLEMENTE CA 92673

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/15/2021
    3. Issuer Name and Ticker or Trading Symbol
    ReShape Lifesciences Inc. [ RSLS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Barton P. Bandy 06/24/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OBLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OBLN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OBLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger

    SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 15, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today the anticipated closing of their previously announced merger to be effective after the close of the market today, June 15, 2021. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market on Wednesday, June 16, 2021, under the name ReShape Lifesciences Inc. and the trading symbol "RSLS."Immediately following the effective time of the merger, existing ReShape stockholders will own 51% and existing Obalon stockholders will own 49% of the outstanding shares of common stock of the

    6/15/21 12:05:00 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger

    SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today that the parties anticipate the closing of their previously announced merger to occur promptly after approval of their pending Nasdaq listing application. While there can be no assurance that the listing application will be approved, Nasdaq approval is the sole remaining condition to closing in the merger agreement (other than conditions that the parties anticipate being satisfied at the closing). Upon the closing of the merger, shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital M

    6/8/21 7:30:00 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    Reminder: Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences

    SAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders (the "Special Meeting") on May 25, 2021, at 8:30 a.m. PT.All stockholders are highly encouraged to vote by phone or email on this critical transaction. Without the required stockholder approval, the merger will not be able t

    5/24/21 7:30:00 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    SEC Filings

    View All

    Obalon Therapeutics, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ReShape Lifesciences Inc. (0001427570) (Filer)

    7/2/21 4:05:32 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    Obalon Therapeutics, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)

    6/15/21 5:11:09 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    Obalon Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)

    6/15/21 12:20:14 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Obalon Therapeutics upgraded by Alliance Global Partners

    Alliance Global Partners upgraded Obalon Therapeutics from Neutral to Buy

    2/18/21 7:35:42 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by ARMISTICE CAPITAL, LLC

    4 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    6/29/21 9:44:48 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    SEC Form 3: STANKOVICH THOMAS claimed ownership of 2,613 units of Common Stock

    3 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    6/24/21 5:29:11 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by McDougal Lori Courtney

    3 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    6/24/21 5:13:50 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    Financials

    Live finance-specific insights

    View All

    Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

    SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreement had been signed on January 19, 2020 for a merger with ReShape Lifesciences Inc. Financial results for the fourth quarter of 2020Revenue for the fourth quarter of 2020 w

    3/12/21 7:12:24 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Obalon Therapeutics, Inc. (Amendment)

    SC 13G/A - ReShape Lifesciences Inc. (0001427570) (Subject)

    6/30/21 6:16:56 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Obalon Therapeutics, Inc. (Amendment)

    SC 13D/A - ReShape Lifesciences Inc. (0001427570) (Subject)

    6/30/21 6:10:33 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Obalon Therapeutics, Inc.

    SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)

    6/25/21 4:21:09 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care